Data analysis shows higher rates of mucosal healing with Entyvio in ulcerative colitis and Crohn's disease.- Takeda.

Takeda Pharmaceutical announced new real-world data evaluating the comparative effectiveness of Entyvio (vedolizumab) and tumor necrosis factor-alpha (TNFalpha)-antagonist therapy in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). These analyses observed that patients with UC treated with Entyvio compared to TNFalpha-antagonist therapy had statistically significant higher 12-month cumulative rates of mucosal healing (50% vs 42%) and clinical remission (54% vs 37%), and numerically higher steroid-free clinical remission rates (49% vs 38%). In CD, results reported statistically significant higher 12-month cumulative rates of mucosal healing (50% vs 41%), and numerically higher rates of clinical remission (38% vs 34%) and steroid-free clinical remission (26% vs 18%) compared to TNFalpha-antagonist therapy.

New clinical data also being presented at ECCO from the Phase IIIb open-label prospective multicenter study (VERSIFY) evaluating the efficacy of Entyvio on complete mucosal healing (absence of ulcerations), endoscopic remission (Simple endoscopic score for CD [SES-CD] less than 4) and endoscopic response (50% decrease in SES-CD from baseline) provide insight into complete mucosal healing in CD. Results at week 26 found Entyvio induced complete mucosal healing (15%), endoscopic remission (12%) and endoscopic response (25%) in the overall population of CD patients, particularly in an anti-TNFalpha-na�ve setting (complete mucosal healing 24%, endoscopic remission 20%, and endoscopic response 28%). These data were presented as oral presentations at the 13th Congress of the European Crohn's and Colitis Organization (ECCO).